Jan H. ter Meulen

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1

Neeta Somaiah, Matthew S. Block, Joseph W. Kim et al. · Clinical Cancer Research · 2019 · 86 citations · Full text

Trial Watch

Fernando Aranda, Erika Vacchelli, Florine Obrist et al. · OncoImmunology · 2014 · 80 citations · Full text

Inflammation, Toll-like Receptors, Cancer Immunosurveillance +13

Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates

Dhanasekaran Govindarajan, Steven Meschino, Liming Guan et al. · Vaccine · 2015 · 75 citations

Vaccination, Protective Efficacy, Preclinical Development +6

First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1

Amit Mahipal, Samuel Ejadi, Sacha Gnjatic et al. · Cancer Immunology Immunotherapy · 2019 · 29 citations · Full text

Medicine, Metronomic Therapy, Pathology +8

HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells

Edmund G. Wee, Beatrice Ondondo, Peter Berglund et al. · Molecular Therapy · 2017 · 20 citations · Full text